Clinical Trial Update: A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) [Phase 2]

View source ↗

Summary

The NAVIGATE Phase 2 study evaluating navitoclax added to bendamustine and rituximab for relapsed diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Navitoclax (navitoclax)
• Rituximab (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: WITHDRAWN